Live tape
Top 8, mentions 7d7,436META2,242 mentions▲ +0.06GOOGL1,493 mentions▲ +0.02NVDA782 mentions▲ +0.09MUSE663 mentions▲ +0.07MSFT600 mentions▲ +0.06SPY565 mentions▲ +0.05QQQ552 mentions▲ +0.08TSLA539 mentions▲ +0.06

Equity · Healthcare

CVS

CVS Health Corporation · NYSE

$99.11 −5.06% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Aug 5, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$115 $95 30 Jun 5 Aug

The line runs $103.31 on 30 June through $99.11 on 5 August, on a scale from $95 to $115. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CVS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $103.31 on 30 June 2026 through $99.11 on 5 August 2026.

Market cap $126.8B
P/E (TTM) 26.2
52-week range $60.01 – $110.58
Avg volume 1.7M

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Aug 5, 2026

CVS insider trades

SEC Form 4

CVS has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 26 June 2026.

Date Insider Type Shares Value
21 May 2026 ROBBINS LARRY Director Sell 370,462 $34.62M
20 May 2026 ROBBINS LARRY Director Sell 1,018,000 $95.51M
19 May 2026 ROBBINS LARRY Director Sell 1,983,538 $187.34M
08 May 2026 Mandadi Tilak EVP, Chief Exp & Tech Officer Sell 69,551 $6.23M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
26 Jun 2026 Clark James David SVP, Cont & Chief Acct Officer Tax withheld 454 $41K
31 May 2026 Compton-Phillips Amy EVP, Chief Medical Officer Tax withheld 7,618 $693K
31 May 2026 Newman Brian EVP, Chief Financial Officer Tax withheld 2,478 $225K
21 May 2026 AGUIRRE FERNANDO Director Other 1,563 $146K
20 May 2026 AGUIRRE FERNANDO Director Other 30,437 $2.85M
14 May 2026 AGUIRRE FERNANDO Director Award 1,563 $152K
14 May 2026 BROWN C DAVID II Director Award 1,544 $150K
14 May 2026 Balser Jeffrey R. Director Award 2,058 $200K
14 May 2026 SANSONE GUY P Director Award 1,447 $141K
14 May 2026 Norwalk Leslie V Director Award 1,447 $141K
14 May 2026 KIRBY J SCOTT Director Award 1,447 $141K
01 Apr 2026 CAPOZZI HEIDI B EVP and Chief People Officer Tax withheld 1,334 $97K

Showing the 12 most recent of 48 compensation filings in this window. The figures above count all of them.

CVS reported financials

SEC EDGAR XBRL

CVS reported revenue of $402.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.8B.

Figure Reported Period
Revenue $402.1B 31 Dec 2025 fiscal year
Net income $1.8B 31 Dec 2025 fiscal year
Diluted EPS $1.39 31 Dec 2025 fiscal year
Total assets $253.8B 30 Jun 2026 at period end
Total equity $79.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CVS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.31 $106.10B
31 Mar 2026 Q1 2026 $2.30 $100.43B
31 Dec 2025 FY 2025 $1.39 $402.07B
30 Sep 2025 Q3 2025 $-3.13 $102.87B
30 Jun 2025 Q2 2025 $0.80 $98.92B
31 Mar 2025 Q1 2025 $1.41 $94.59B
31 Dec 2024 FY 2024 $3.66 $372.81B
30 Sep 2024 Q3 2024 $0.07 $95.43B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CVS institutional holders

SEC Form 13F

15 of the 45 institutional funds we track reported a CVS position for the quarter ended 30 Jun 2026 — a combined $2.4B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Glenview Capital Management Trimmed −41.1% shares 4,824,799 $499.1M
Citadel Advisors Held (±25%) −11.3% shares 4,812,530 $497.9M
Viking Global Investors New position 3,663,361 $379.0M
AQR Capital Management Held (±25%) +1.0% shares 2,411,937 $248.9M
Millennium Management Added +1,013.6% shares 2,164,833 $224.0M
Point72 Asset Management New position 1,961,032 $202.9M
D. E. Shaw & Co. Held (±25%) −14.6% shares 1,382,037 $143.0M
Renaissance Technologies Added +67.6% shares 441,016 $45.6M
Bridgewater Associates Trimmed −28.7% shares 440,972 $45.6M
Tudor Investment Corp Trimmed −45.7% shares 370,000 $38.3M

Showing the 10 largest of 15 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

CVS fails-to-deliver

SEC CNS data

On 28 Aug 2026, 632 shares of CVS failed to deliver (about $59K) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
28 Aug 2026 632 $59K <0.001%
27 Aug 2026 2,918 $275K <0.001%
26 Aug 2026 2,808 $261K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in CVS

STOCK Act disclosures

The most recent congressional trade disclosed in CVS is a sale by Dwight Evans (house, PA), dated 21 Nov 2025.

Date Member Type Amount
21 Nov 2025 filed 15 May 2026 Dwight Evans house · Democrat–PA Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures